乳腺癌化疗患者应用输液港的效果、常见问题分析及对策

摘要
图/表
参考文献(20)
相关文章 (15)

全文: PDF (0 KB) HTML (37 KB)
输出: BibTeX | EndNote (RIS)

摘要目的分析乳腺癌化疗应用输液港的常见问题并提出解决措施，探讨输液港在乳腺癌化疗中的应用效果。方法选取2014年1～12月我院施行输液港治疗的158例乳腺癌患者作对照组，回顾性分析其常见的临床护理问题，分析原因并提出针对性解决措施。选取2015年1～12月收治的行输液港治疗的180例乳腺癌患者作为观察组，在护理过程中执行相应的解决方案，比较两组的不良事件发生率、患者满意度。结果观察组的不良事件发生率显著低于对照组，差异有统计学意义（3.33%vs.13.29%，P＜0.05）。观察组的患者满意度评分显著高于对照组，差异有统计学意义[（86.7±6.9）vs.（75.3±7.3），P＜0.05]。结论在乳腺癌化疗患者行输液港治疗过程中，应加强巡视和检查，对出现的不良事件进行分析，采取针对性护理，能显著提高患者的满意度，降低不良事件发生率。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	程燕云
	陈荣霞
	吴倩芳

关键词 ：输液港, 乳腺癌, 护理

Abstract：Objective To analyze the common problems in the application of transfusion port in the chemotherapy of breast cancer,and put forward the solution,to explore the application effect of transfusion port in the chemotherapy of breast cancer.Methods 158 cases of breast cancer treated by transfusion port in our hospital from January to December in 2014 were selected as the control group,the common clinical nursing problems were analyzed retrospectively,the causes were analyzed and the corresponding measures were put forward.180 cases of breast cancer treated by transfusion port in our hospital from January to December in 2015 were selected as the observation group,and the corresponding solutions were carried out in the nursing process.The incidence rate of adverse events and patient satisfaction were compared between the two groups.Results The incidence rate of adverse events in the observation group was lower than that in the control group,with significant difference(3.33%vs.13.29%,P＜0.05).The patients satisfaction score in the observation group was higher than that in the control group,with significant difference[(86.7±6.9)vs.(75.3±7.3),P＜0.05]. Conclusion In the treatment process of breast cancer chemotherapy patients treated by infusion port,the inspection and examination should be strengthened,the adverse events were analyzed,which can significantly improve the satisfaction of patients,reduce the incidence rate of adverse events.

Key words： Transfusion port Breast cancer Nursing

引用本文:

程燕云；陈荣霞；吴倩芳. 乳腺癌化疗患者应用输液港的效果、常见问题分析及对策[J]. 中国当代医药, 2017, 24(1): 189-191.
CHENG Yan-yun；CHEN Rong-xia；WU Qian-fang. Effect,common problems and countermeasures of transfusion port in patients with breast cancer undergoing chemotherapy. 中国当代医药, 2017, 24(1): 189-191.

链接本文:

http://dangdaiyiyao.com/CN/ 或 http://dangdaiyiyao.com/CN/Y2017/V24/I1/189

[1]	洪金花.输液港在肿瘤患者中的应用研究[J].中国当代医药，2013，20（30）：124-125.
[2]	Guo JR，Xu F，Jin XJ，et al.Impact of allogenic and autologous transfusion on immune function in patients with tumors[J]. Asian Pac J Cancer P，2014，15（1）：467-474.
[3]	张建军.新辅助化疗联合保乳术治疗乳腺癌的临床效果分析[J].中国当代医药，2014，21（30）：47-49.
[4]	牟鹏，厉红元.乳腺癌新辅助化疗的研究进展[J].中国普外基础与临床杂志，2011，18（9）：1011-1016.
[5]	Song MG，Seo TS，Kang EY，et al.Innominate vein stenosis in breast cancer patients after totally implantable venous access port placement[J].J Vasc Access，2015，26（2）：315-320.
[6]	Zhou J，Qian S，He W，et al.Implanting totally implantable venous access port via the internal jugular vein guided by ultrasonography is feasible and safe in patients with breast cancer[J].World J Surg Oncol，2014，12（12）：1-7.
[7]	付小伟，孙洪涛，顾志菊，等.植入式静脉输液港的临床应用及护理[J].实用临床医药杂志，2013，17（4）：59-62.
[8]	石果，罗凤，张玲.172例乳腺癌输液港静脉血栓相关因素分析[J].重庆医科大学学报，2016，41（5）：530-533.
[9]	Ferreira S.Implantable venous access port[J].Krankenpfl Soins Infirm，2012，105（9）：62-64.
[10]	Lebeaux D，Fernández-Hidalgo N，Chauhan A，et al.Management of infections related to totally implantable venous-access ports：challenges and perspectives[J].Lancet Infect Dis，2014，14（2）：146-159.
[11]	Lebeaux D，Larroque B，Gellendautremer J，et al.Clinical outcome after a totally implantable venous access port-related infection in cancer patients：a prospective study and review of the literature[J].Medicine，2012，91（6）：309-318.
[12]	Narducci F，Jean-Laurent M，Boulanger L，et al.Totally implantable venous access port systems and risk factors for complications：a one-year prospective study in a cancer centre[J].Eur J Surg Oncol，2011，37（10）：913-918.
[13]	Pohl F，Hartmann W，Holzmann T，et al.Risk of infection due to medical interventions via central venous catheters or implantable venous access port systems at the middle port of a three-way cock：luer lock cap vs.luer access split septum system（Q-Syte）[J].BMC Infect Dis，2014，14（1）：41.
[14]	俞新燕，干群，蔡晓洁.植入式静脉输液港在晚期乳腺癌化疗患者中的应用及护理[J].浙江创伤外科，2010，15（3）：414.
[15]	陈丽莉，何惠燕，毛晓群.乳腺癌患者应用植入式中心静脉输液港的常见问题与对策[J].中华护理杂志，2011，46（11）：1116-1117.
[17]	王寅欢，陈显春，曾令娟.乳腺癌患者植入静脉输液港并发症原因分析及护理对策[J].齐鲁护理杂志，2016，22（16）：68-70.
[18]	陶文静.2例乳腺癌患者静脉输液港并发导管堵塞的原因及护理对策[J].中外医学研究，2016，14（18）：80-81.
[20]	陈丽莉，何惠燕，毛晓群.乳腺癌患者应用植入式中心静脉输液港的常见问题与对策[J].中华护理杂志，2011，46（11）：1116-1117.
[16]	Bassi KK，Giri AK，Pattanayak M，et al.Totally implantable venous access ports：retrospective review of long-term complications in 81 patients[J].Indian J Cancer，2012，49（1）：114-118.
[19]	Seo TS，Song MG，Kang EY，et al.Abstract No.505.Central veinstenosisinbreastcancerpatientsaftertotallyimplantable venous access port placement[J].J Vasc Interv Radiol，2015，26（2）：S218.